Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.
Lenalidomide maintenance extended disease control in some chronic lymphocytic leukemia patients, but side effects were significant and survival didn't improve.
In a 143-patient phase III trial, lenalidomide maintenance after initial immunochemotherapy prolonged progression-free survival in chronic lymphocytic leukemia with residual disease. The treatment also increased cytopenias, infections, and gastrointestinal adverse effects and did not improve overall survival.
What the study was
- Study design
- Randomized multicenter phase III trial
- Population
- Patients with chronic lymphocytic leukemia and measurable residual disease after initial immunochemotherapy
- Sample size
- 143
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- British journal of haematology
Why it surfaced
A phase III randomized trial provides direct clinical evidence in a watchlist malignancy, with a meaningful progression-free survival result but no overall-survival benefit.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.